Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Net Margin (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Net Margin for 7 consecutive years, with 31552.47% as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Net Margin fell 2798079.0% year-over-year to 31552.47%, compared with a TTM value of 52939.68% through Mar 2024, down 4626371.0%, and an annual FY2023 reading of 38238.15%, down 3463939.0% over the prior year.
  • Net Margin was 31552.47% for Q2 2023 at Spyre Therapeutics, down from 9304.04% in the prior quarter.
  • Across five years, Net Margin topped out at 56.15% in Q2 2021 and bottomed at 31552.47% in Q2 2023.
  • Average Net Margin over 3 years is 7630.69%, with a median of 3571.68% recorded in 2022.
  • The sharpest move saw Net Margin crashed -351553bps in 2022, then crashed -2798079bps in 2023.
  • Year by year, Net Margin stood at 561.09% in 2021, then tumbled by -1894bps to 11188.1% in 2022, then plummeted by -182bps to 31552.47% in 2023.
  • Business Quant data shows Net Margin for SYRE at 31552.47% in Q2 2023, 9304.04% in Q1 2023, and 11188.1% in Q4 2022.